Brovudine cream for treating herpes zoster and preparation method thereof
By using an oil-in-water emulsion formulation, 15-hydroxystearic acid polyethylene glycol ester as an emulsifier and behenic acid glyceryl ester as an oil phase matrix, the problem of strong irritation and safety risks of brovodin formulation is solved, and a therapeutic effect with good safety, few side effects and high stability is achieved.
CN121489855AInactive Publication Date: 2026-02-10ZHEJIANG REACHALL PHARMA
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202512018802.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-30
- Publication Date
- 2026-02-10
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Existing brovofuran formulations are highly irritating and have poor comfort, and the safety risks associated with metal oxide additives lead to increased side reactions.
Method used
The formula is an oil-in-water emulsion containing 0.1-5% brivudine, 5-45% organic solvent, 0.3-10% emulsifier, and 15-55% oil phase matrix. 15-hydroxystearic acid polyethylene glycol ester is used as the emulsifier, and glyceryl behenate can be used as the oil phase matrix to replace metal oxides, forming a stable emulsion.
Benefits of technology
A brivudine cream with good safety, few side effects, and high stability is provided, which is suitable for the treatment of herpes zoster and other skin diseases, improving the treatment effect and user comfort.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses a brovudine cream for treating herpes zoster and a preparation method of the brovudine cream. Specifically, the invention provides a cream which comprises the following components in percentage by mass: 0.1-5% of bromovudine, 5-45% of an organic solvent, 0.3-10% of an emulsifier, 15-55% of an oil phase matrix and water, the cream is an oil-in-water type cream; and any one of the following conditions is met: (C1) the emulsifier comprises 15-hydroxystearic acid polyethylene glycol ester; (C2) the oil phase matrix comprises glyceryl behenate. The brovudine cream provided by the invention has one or more positive progressive effects of good safety, small side reaction, good stability and good treatment effect.
Need to check novelty before this filing date? Find Prior Art